推荐产品
生物来源
mouse
质量水平
抗体形式
purified immunoglobulin
抗体产品类型
primary antibodies
克隆
7B2.5, monoclonal
种属反应性
human
制造商/商品名称
Chemicon®
技术
flow cytometry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
同位素/亚型
IgG3
NCBI登记号
UniProt登记号
运输
wet ice
靶向翻译后修饰
unmodified
基因信息
human ... BCL2L1(598)
相关类别
特异性
Apoptosis, or programmed cell death, is a well-documented phenomenon in many cellular systems (Cohen, 1991). It plays a key role in tissue and organ development, as well as in adult tissues during cell turnover. Apoptosis can be induced by a variety of internal and external stimuli including growth factor deprivation, cytokine treatment, antigen-receptor engagement, cell-cell interactions, irradiation and glucocorticoid treatment (Cohen & Duke, 1992). Bcl-2 and one of its homologues, Bcl-XL, protect cells from apoptosis (Nunez & Clarke, 1994; Cory, 1995), while other homologues of Bcl-2 such as Bax, Bad and Bak have been shown to enhance apoptosis (Oltvai, 1993; Farrow, 1995; Chittenden, 1995; Kiefer, 1995). Bcl-XL has been shown to block apoptosis which is induced by a variety of stimuli and, under certain conditions, offers greater protection against apoptosis than Bcl-2 (Boise, 1993; Gottschalk, 1994; Gonzalez-Garcia, 1995; Dole, 1995; Shimizu, 1995). In contrast, Bad and Bax inhibit the protective functions of Bcl-XL and Bcl-2, respectively. Although heterodimerization between Bcl-XL, Bad and Bcl-2/Bax was originally thought to be essential for the differential anti-apoptotic activity of Bcl-XL and Bcl-2 (Oltvai, 1993; Yin, 1994); other results suggest that the formation of heterodimers may not be necessary for this death-repressing activity Cheng, 1996; Gottschalk, 1996). This antibody recognizes Human Bcl-XL (Mr 29 kDa) and Bcl-Xs (Mr 21 kDa).
免疫原
Recombinant Bcl-XS.
应用
Detect Bcl-XL & BclXs using this Anti-Bcl-XL & BclXs Antibody, clone 7B2.5 validated for use in FC, IP, WB, IH.
Flow cytometry:
Immunoprecipitation (Cheng, 1996; Gottschalk, 1996)
Immunohistochemistry (Foreman, 1996; Wrone-Smith, 1995)
Western blotting: ( 0.5 μg/mL)
Optimal working dilutions must be determined by end user.
Immunoprecipitation (Cheng, 1996; Gottschalk, 1996)
Immunohistochemistry (Foreman, 1996; Wrone-Smith, 1995)
Western blotting: ( 0.5 μg/mL)
Optimal working dilutions must be determined by end user.
Research Category
Apoptosis & Cancer
Apoptosis & Cancer
Research Sub Category
BCL2 & Inhibition
BCL2 & Inhibition
外形
Format: Purified
Purified immunoglobulin - Ig fraction. Liquid in borate buffer saline, pH 8.2.
储存及稳定性
Store at 2-8°C for up to 12 months.
其他说明
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
法律信息
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
警示用语:
Danger
危险声明
危险分类
Repr. 1B
储存分类代码
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
WGK
nwg
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Molecular cancer research : MCR, 6(5), 751-759 (2008-05-07)
BRAF-activating mutations have been reported in several types of cancer, including melanoma ( approximately 70% of cases), thyroid (30-70%), ovarian (15-30%), and colorectal cancer (5-20%). Mutant BRAF has constitutive kinase activity and causes hyperactivation of the mitogen-activated protein kinase pathway.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门